Dulaglutide (Italian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Dulaglutide" in Italian language version.

refsWebsite

Global rank Italian rank

6nih.gov

4^th place

9^th place

4doi.org

2^nd place

7^th place

1informahealthcare.com

low place

1fda.gov

447^th place

644^th place

1jst.go.jp

1,903^rd place

3,782^nd place

1archive.org

6^th place

8^th place

1prous.com

low place

1oadoi.org

799^th place

22^nd place

archive.org

Nauck M, Weinstock RS, Umpierrez GE, Guerci B, Skrivanek Z, Milicevic Z, Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5), in Diabetes Care, vol. 37, n. 8, agosto 2014, pp. 2149–58, DOI:10.2337/dc13-2761, PMID 24742660.

doi.org

dx.doi.org

Nadkarni P, Chepurny OG, Holz GG, Regulation of glucose homeostasis by GLP-1, in Prog Mol Biol Transl Sci, vol. 121, 2014, pp. 23–65, DOI:10.1016/B978-0-12-800101-1.00002-8, PMC 4159612, PMID 24373234.
Nauck M, Weinstock RS, Umpierrez GE, Guerci B, Skrivanek Z, Milicevic Z, Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5), in Diabetes Care, vol. 37, n. 8, agosto 2014, pp. 2149–58, DOI:10.2337/dc13-2761, PMID 24742660.
Amblee A, Dulaglutide for the treatment of type 2 diabetes, in Drugs Today, vol. 50, n. 4, aprile 2014, pp. 277–89, DOI:10.1358/dot.2014.50.4.2132740, PMID 24918645. URL consultato il 30 settembre 2014.
Monami M, Dicembrini I, Nardini C, Fiordelli I, Mannucci E, Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials, in Diabetes Res. Clin. Pract., vol. 103, n. 2, febbraio 2014, pp. 269–75, DOI:10.1016/j.diabres.2014.01.010, PMID 24485345. URL consultato il 30 settembre 2014.

fda.gov

http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm415180.htm Comunicato FDA

informahealthcare.com

Courtney Aavang Tibble, Tricia Santos Cavaiola,Robert R Henry, Longer acting GLP-1 receptor agonists and the potential for improved cardiovascular outcomes: a review of current literature, Expert Review of Endocrinology & Metabolism ^{[collegamento interrotto]}, su informahealthcare.com, Informa Healthcare. URL consultato il 29 settembre 2014.

jst.go.jp

joi.jlc.jst.go.jp

Terauchi Y, Satoi Y, Takeuchi M, Imaoka T, Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study, in Endocr. J., luglio 2014, PMID 25029955. URL consultato il 29 settembre 2014.

nih.gov

ncbi.nlm.nih.gov

Jimenez-Solem E, Rasmussen MH, Christensen M, Knop FK, Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes, in Curr. Opin. Mol. Ther., vol. 12, n. 6, dicembre 2010, pp. 790–7, PMID 21154170.
Nadkarni P, Chepurny OG, Holz GG, Regulation of glucose homeostasis by GLP-1, in Prog Mol Biol Transl Sci, vol. 121, 2014, pp. 23–65, DOI:10.1016/B978-0-12-800101-1.00002-8, PMC 4159612, PMID 24373234.
Terauchi Y, Satoi Y, Takeuchi M, Imaoka T, Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study, in Endocr. J., luglio 2014, PMID 25029955. URL consultato il 29 settembre 2014.
Nauck M, Weinstock RS, Umpierrez GE, Guerci B, Skrivanek Z, Milicevic Z, Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5), in Diabetes Care, vol. 37, n. 8, agosto 2014, pp. 2149–58, DOI:10.2337/dc13-2761, PMID 24742660.
Amblee A, Dulaglutide for the treatment of type 2 diabetes, in Drugs Today, vol. 50, n. 4, aprile 2014, pp. 277–89, DOI:10.1358/dot.2014.50.4.2132740, PMID 24918645. URL consultato il 30 settembre 2014.
Monami M, Dicembrini I, Nardini C, Fiordelli I, Mannucci E, Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials, in Diabetes Res. Clin. Pract., vol. 103, n. 2, febbraio 2014, pp. 269–75, DOI:10.1016/j.diabres.2014.01.010, PMID 24485345. URL consultato il 30 settembre 2014.

oadoi.org

Monami M, Dicembrini I, Nardini C, Fiordelli I, Mannucci E, Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials, in Diabetes Res. Clin. Pract., vol. 103, n. 2, febbraio 2014, pp. 269–75, DOI:10.1016/j.diabres.2014.01.010, PMID 24485345. URL consultato il 30 settembre 2014.

prous.com

journals.prous.com

Amblee A, Dulaglutide for the treatment of type 2 diabetes, in Drugs Today, vol. 50, n. 4, aprile 2014, pp. 277–89, DOI:10.1358/dot.2014.50.4.2132740, PMID 24918645. URL consultato il 30 settembre 2014.